On day 25 post-primary tumor inoculation, ACT-DC exhibited a 6.9-fold and 9.1-fold greater efficacy in reducing tumor size compared to cDC1+NPNeg and cDC1+NPPEG, respectively. The gene discussed is MPPE1; the disease is neoplasm.